JCO

Beyond's analysis on JCO

• 2026-09-14 — Kelun-Biotech reports Phase III results for its HER2-targeted antibody-drug conjugate trastuzumab botidotin versus the established T-DM1 in HER2-positive breast cancer, with findings published in the Journal of Clinical Oncology

Recent news mentioning JCO

• 2026-09-14 — Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO

Appears alongside

• III

Browse the full archive →